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New series of benzenesulfonamide derivatives incorporating pyrazole and isatin moieties were prepared
using celecoxib as lead molecule. Biological evaluation of the target compounds was performed against
the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more precisely against the human isoforms
hCA I, II (cytosolic), IX and XII (transmembrane, tumor-associated enzymes). Most of the tested com-
pounds efficiently inhibited hCA I, II and IX, with KIs of 2.5e102 nM, being more effective than the
reference drug acetazolamide. Compounds 11e, 11f, 16e and 16f were found to inhibit hCA XII with Ki of
3.7, 6.5, 5.4 and 7.2 nM, respectively. Compounds 11e and 16e, with 5-NO2 substitution on the isatin ring,
were found to be selective inhibitors of hCA IX and hCA XII. Docking studies revealed that the NO2 group
of both compounds participate in interactions with Asp132 within the hCA IX active site, and with
residues Lys67 and Asp130 in hCA XII, respectively.
© 2015 Elsevier Masson SAS. All rights reserved.1. Introduction
The sulfonamides and their isosters such as the sulfamates
and sulfamides, are well known carbonic anhydrase (CA, EC
4.2.1.1) inhibitors (CAIs) and are in clinical use for almost 70
years for the treatment of glaucoma, obesity, epilepsy and as
diuretics [1]. The large use of CAIs for pharmaceutical applica-
tions relies on the wide distribution of the 15 human (h) CA
isoforms within different tissues as well as on their involvement
in many physiological/pathological conditions. Antiglaucoma
CAI-drugs mainly target CA II, IV and XII; the diuretics CA II, IV,
XII and XIV; the antiepileptics CA VII and XIV [2-5]. The selective
inhibition of CA IX and XII produces significant antitumor and, Sezione di Scienze Farm-
. Schiff 6, 50019 Sesto Fior-
utical Chemistry, College of
h 11451, Saudi Arabia.
bdel-Aziz), claudiu.supuran@
served.antimetastatic effects. However the main drawback associated to
the use of sulfonamide CAIs is represented by the lack of selec-
tivity in inhibiting the various isoforms, thus leading to a
plethora of side effects [6,7]. In this contest many efforts have
been made for the development of isoform-selective CAIs, and
some remarkable results have been achieved in the last 15 years
since the introduction of the tail approach [6-8]. Currently a
sulfonamide CA IX inhibitor (SLC-0111) entered in Phase I clinical
studies for the treatment of hypoxic, advanced stage solid tu-
mors [8-10]. Furthermore, novel CAI classes such as the poly-
amines, [11] phenols, [12] dithiocarbamates, [13] xanthates [14]
coumarins, thiocoumarins, 2-thioxo-coumarins and coumar-
inoximes [1,4,15-17] were discovered and the inhibition mecha-
nisms of many of these compounds were explained by using
kinetic, spectroscopic and X-ray crystallographic techniques
[2,6,12,13].
Recently, benzyl aniline sulfonamides such as Iwere reported as
hCA IX inhibitors (Ki¼ 1.8e27 nM) [18]. The same group developed
similar compounds such as the cyclic form II, which selectively
inhibited hCA IX (with Ki of 13e27 nM) versus hCA I/II [19]. The lead
molecule of these derivatives was celecoxib III which was
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(Ki¼ 21 nM) inhibitor by one of our groups [20]. In addition, other
studies were reported on five membered heterocyclic N-benzene
sulfonamide IV possessing an amino group instead of the aryl one
found in compounds II and III. Compound IV showed excellent
inhibitory action against hCA IX (Ki¼ 6.3 nM) and hCA XII
(Ki¼ 0.74 nM) [21] (Fig. 1).
A series of 4-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-1-(5-
substituted-oxoindolin-3-ylidene)semicarbazides V was recently
evaluated as carbonic anhydrase inhibitors and displayed inter-
esting activity against hCA I and IX (X¼NO2, Ki¼ 5.95 and 1.25 mM,
respectively) [22]. The Schiff base VI showed a potent inhibitory
activity against hCA IX (Ki¼ 1.1 nM) and had a high selectivity for
isoform hCA IX compared to the cytosolic isozymes hCA I and hCA II
[23] (Fig. 1).
Based on these literature data, we report here the synthesis of
three novel series of isatin-pyrazole-benzenesulfonamide hybrids
5aed,11aef and 16aef as CAIs. The design of the new hybrids relies
on grafting the oxindole hydrazine carbonyl moiety from the isatin
semicarbazide derivatives V to the 4-(5-phenyl-1H-pyrazol-1-yl)
benzenesulfonamide scaffold found compounds II and III, at either
position 3 (5aed ) or 4 (11aef) of the pyrazole ring. The additive
effect of combining these pharmacophore moieties might produce
compounds with high CA inhibitory activity. Furthermore, the
structure modification in the third series 16aef involved replace-
ment of the 5-phenyl ring in 11aef by an amino group in analogy to
the potent CAI IV mentioned above (Fig. 1).Fig. 1. Chemical structure of compounds IeVI and2. Results and discussion
2.1. Chemistry
The synthesis of the first series of sulfonamides, 5aed, is pre-
sented in Scheme 1. The classical Claisen condensation of aceto-
phenone (1) with diethyl oxalate in the presence of sodium
ethoxide gave ethyl 2,4-dioxo-4-phenylbutanoate (2). The regio-
selective cyclization of butanoate 2 with 4-
aminosulfonylphenylhydrazine [24] was achieved in acetic acid,
yielding ethyl 5-phenyl-1-(4-sulfamoylphenyl)-1H-pyrazole-3-
carboxylate (3) which was then reacted with hydrazine hydrate
to afford hydrazide 4. Hydrazones 5aedwere obtained by refluxing
hydrazide 4with the appropriate isatin derivative in ethanol, in the
presence of catalytic amounts of acetic acid.
The IR spectrum of the unreported hitherto 4-(3-(hydrazine-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (4)
showed absorption bands due to NH2 and NH groups at 3334-
3196 cm1, beside the absorption peak of C]O group at
1674 cm1and two absorption bands of the SO2 group at 1319 and
1153 cm1. Its 1H-NMR spectrum revealed three D2O exchangeable
singlet signals corresponding to SO2NH2, NHeNH2 and NHeNH2 at
d 7.51, 9.69 and 4.61 ppm, respectively. The characteristic singlet
signal of H-4 of pyrazole appeared at d 7.06 ppm.
The structure hydrazones 5aedwas confirmed by their 1H-NMR
spectra which revealed the disappearance of the hydrazide NH2
signal in compound 4 in addition to the appearance of the signal ofthe targeted hybrids 5aed, 11aef and 16aef.
Scheme 1. Synthesis of compounds 5aed. Reagents and conditions: (i) (COOEt)2/NaOC2H5/EtOH/0 C; (ii) p-SO2NH2C6H4NHNH2/AcOH/reflux 1 h; (iii) N2H4.H2O/reflux 3 h; (iv) 5-
(Un)substituted isatin/EtOH/AcOH/reflux 1 h.
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spectra of 5aed showed downfield shifts of the hydrazide NH
signal, which appeared in the range d 11.59e14.16 ppm. Moreover,
the 1H-NMR spectrum of 5d showed a signal of aliphatic protons
(CH3 group) at d 2.30 ppm. The 13C-NMR spectrum of 5d showed
the signals of C]O groups at d 157.50 and 162.61 ppm, in addition
to the signal of the aliphatic carbon (CH3 group) at d 20.48 ppm.
Preparation of the second series of sulfonamides (11aef) was
achieved as illustrated in Scheme 2. Ethyl benzoyl acetate (7) was
synthesized by condensation of ethyl acetoacetate (6)with benzoyl
chloride in sodium ethoxide followed by hydrolysis in the presence
of aqueous NH3 and NH4Cl. Refluxing 7 with DMF-DMA afforded
ethyl 2-benzoyl-3-(dimethylamino)acrylate (8) which was
employed in the next step without further purification. The reac-
tion of the latter enaminonewith 4-aminosulfonylphenylhydrazine
hydrochloride in refluxing ethanol produced the pyrazole ester 9.
The ester 9 was subjected to hydrazinolysis by fusion with hydra-
zine hydrate to give the corresponding hydrazide 10. Hydrazones
11aef were synthesized by the reaction of hydrazide 10 with the
appropriate isatin derivative in ethanol and in the presence of
catalytic amount of acetic acid.
The 1H NMR spectra of ester 9, hydrazide 10 and hydrazones
11aef showed the characteristic signal of H-3 of the pyrazole ring
in the region d¼ 8.19e8.83 ppm. However, single crystal X-ray
analysis of hydrazide 10 gave an absolute confirmation for the
structure of the latter compound and excluded the other possible
positional isomer (Fig. 2) and (see also Supplementary Figure 1).
The 1H-NMR spectrum of 11d revealed the appearance of a
signal due to the aliphatic proton of the OCH3 group at d 3.77 ppm,
whereas the carbon of the same group appeared at d 55.58 ppm in
the 13C-NMR spectrum. The 1H-NMR spectrum of 11f presented one
singlet signal characteristic of benzylic protons ( at d 4.93 ppm),
whilst the carbon of the same group appeared at d 42.96 ppm in the
13C NMR spectrum.
The synthetic pathway of the third series of sulfonamides,16aef, is depicted in Scheme 3. The reaction of ethyl cyanoacetate
(12) with triethyl orthoformate in the presence of acetic anhydride
generated ethyl (ethoxyethylene)cyanoacetate (13) which was then
converted to pyrazole 14 by treatment with 4-
aminosulfonylphenylhydrazine in a mixture of acetic acid and
water (5:1). The structure of compound 14was confirmed by X-ray
crystallography (Fig. 3) and (Supplementary Figure 2). Conse-
quently, hydrazinolysis of the latter ester led to the formation of
hydrazide 15 which reacted with different isatins in refluxing
ethanol to yield hydrazones 16aef.
The IR spectra of compounds 16aef contained bands of the NH2
and NH groups in the range of 3120e3421 cm1. Their 1H-NMR
spectra had D2O exchangeable signals related to 5-amino protons at
d 6.52e7.07 ppm, in addition to D2O exchangeable singlet signals
attributed to protons of the sulfonamide group at around
d 7.49 ppm, isatin NH proton (in 16aee) in the range
d 10.55e11.50 ppm and the hydrazide NH proton in the range
d 11.24e13.10 ppm. In this series, 1H-NMR spectroscopy revealed
the characteristic signal of H-3 of the pyrazole in the range
d 8.20e9.18 ppm, while the 13C-NMR spectra showed a character-
istic signal due to the C-5 of pyrazole ring between
d 94.24e95.72 ppm.
Compound 16d had a signal of aliphatic protons (OCH3 group) at
d 3.79 ppm in its 1H-NMR spectrum and at d 56.09 ppm in its 13C-
NMR spectrum. The benzylic protons of 16f appeared at d 5.02 ppm
in 1H NMR and the benzylic carbon was detected at d 43.00 ppm in
the 13C-NMR spectrum.
2.2. Carbonic anhydrase inhibition
Inhibition data against four physiologically relevant hCA iso-
forms, hCA I, II (cytosolic) as well as hCA IX and XII (trans-
membrane, tumor-associated isoforms), are shown in Table 1 and
were determined by a stopped-flow CO2 hydrase assays. [25].
The following SAR is evident from the data of Table 1:
Scheme 2. Synthetic pathway of compounds 11aef. Reagents and conditions: (i) PhCOCl, NaOC2H5; (ii) NH3, NH4Cl, H2O; (iii) DMF-DMA / Reflux / 2h; (iv) p-SO2NH2C4H6NHNH2.HCl
/ EtOH / Reflux 4 h; (v) N2H4.H2O/reflux 3 h; (vi) 5-(Un)substituted isatin or N-benzyl isatin / EtOH / AcOH /reflux 1 h.
Fig. 2. ORTEP diagram of compound 10.
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sulfonamides 5, 11 and 16 reported here, with KIs ranging
between 5.2 and 102 nM. Otherwise, 5b which was slightly
less effective (KI of 102 nM) all the other compounds were
low nanomolar inhibitors of this isoform whose physiologic
function is still not well understood. Acetazolamide, aclinically used sulfonamide, was a much weaker CAI
compared to the new compounds reported here (KI of
250 nM).
(ii) hCA II, the physiologically dominant isoform was highly
inhibited by all the compounds reported here, with low
nanomolar efficacy (KIs ranging between 2.9 and 31.3 nM),
Scheme 3. Synthetic pathway of compounds 16aef. Reagents and conditions: (i) Triethylorthoformate/acetic anhydride/reflux 10 h; (ii) p-SO2NH2C6H4NHNH2.HCl/Acetic acid/H2O/
Reflux 4 h; (iii) N2H4.H2O/reflux 4 h; (iii) 5-(Un)substituted isatin or N-benzyl isatin/EtOH/AcOH/reflux 1 h.
Fig. 3. ORTEP diagram of compound 14.
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scaffolds led to extremely effective hCA II inhibitors
(Except for compounds 11e, 11f, 16e and 16f which were
fairly less active than AAZ and 5a that had the same ef-
ficacy as AAZ, the other compounds were much better hCA
II inhibitors compared to the standard drug, Table 1).
(iii) The tumor-associated hCA IX was also a highly inhibited by
sulfonamides reported here, with KIs ranging between 2.5
and 52.9 nM. A part for 11a which was slightly less effective
as hCA IX inhibitors, all other synthesized derivatives
showed inhibition constants 20 nM, being thus highly
effective for inhibiting this tumor-associated enzyme, a
validated antitumor target.(iv) hCA XII was also inhibited by sulfonamides reported here
with KIs ranging between 3.7 and 244 nM (Table 1). Except
for compounds 11e, 11f, 16e and 16f, hCA XII was less effi-
ciently inhibited by the new derivatives than the other three
isoforms. In fact compound 11e showed higher activity than
AAZ (KI¼ 3.7 and 5.7 nM, respectively), whereas 11f,16e and
16f had comparable potency to the reference drug (KI¼ 6.5,
5.4 and 7.2 nM, respectively).
It can be observed that moving the oxindole hydrazine carbonyl
moiety on the pyrazole ring from position 3 in 5aed to position 4 in
11aed and 16aed enhanced the inhibitory activity against hCA I, II
and XII isoforms. On the other hand, no clear relationship was
Table 1
Inhibition data of human carbonic anhydrase isoforms hCA I, II, IX and XII with the
sulfonamide derivatives 5, 11 and 16 determined by stopped-flow CO2 hydrase assay
[33], using acetazolamide (AAZ) as standard drug.
Compound Ki(nM)a
hCA I hCA II hCA IX hCA XII
5a 53.7 11.8 8.8 91.5
5b 102 9.9 7.4 65.9
5c 9.0 6.4 20.0 83.6
5d 52.4 5.9 4.7 244
11a 9.7 4.3 52.9 73.5
11b 38.3 4.6 9.7 44.5
11c 6.7 5.5 7.8 91.4
11d 7.6 3.5 3.3 74.6
11e 49.5 31.3 15.7 3.7
11f 61.9 17.9 13.6 6.5
16a 5.7 2.9 2.8 37.7
16b 7.1 3.8 2.5 22.8
16c 5.2 3.2 9.4 56.8
16d 7.1 4.5 3.5 82.8
16e 70.4 23.1 7.4 5.4
16f 14.9 19.5 20.0 7.2
AAZb 250 12 25 5.7
a Ki presented is the mean from 3 different assays; errors are in the range of ±
5e10% of the reported values (data not shown).
b Acetazolamide (AAZ) was used as a standard inhibitor for all CAs investigated
here.
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forms and replacement of the phenyl ring at position 5 of the
pyrazole moiety in 11aef with an amino group in 16aef.
Regarding the effect of the substitution pattern on the isatin
moiety, it was observed that the introduction of a NO2 group to
position 5 of the isatin led to compounds which preferentially
inhibited hCA IX and hCA XII over hCA I and hCA II, as evident for
derivatives 11e and 16e. Meanwhile, N-benzyl substitution on the
isatin moiety, as in 11f and 16f, led to an increased affinity of these
derivatives for hCA XII.2.3. Molecular docking studies
Docking studies were employed to analyze the binding pattern
of compounds 11e and 16e to the tumor associated hCA IX and hCAFig. 4. (A) 3D diagram for interaction of compound 11e with hCA IX (PDB id: 3IAI) show
electrostatic bond. (B) 3D diagram for interaction of compound 16e with hCA IX (PDB id: 3IA
with electrostatic bond. In these diagrams, the whole protein was displayed as a tube except
green dots, electrostatic bond was represented by orange dots, Pi-hydrophobic interaction
interpretation of the references to colour in this figure legend, the reader is referred to theXII isoforms. These studies revealed significant information about
the binding mode of these compounds, and showed the crucial role
of the sulfonamide as a zinc binding group [19] . Docking of com-
pound 11e within the active site of hCA IX revealed the same
important role of the deprotonated sulfonamide moiety, which
interacts with zinc ion and the neighbor residues Leu198 and
Thr199 (Fig. 4A), whereas for 16e, the sulfonamide group forms H-
bond with Thr199 beside the coordination bond to the Zn(II) ion
(Fig. 4B). Moreover, the 5-NO2 substituent of isatin moiety pre-
sented an important role in the interaction of both compoundswith
hCA IX by forming an electrostatic bond with Asp132 (Fig. 4A and
B).
As for hCA IX; the binding of 11e and 16e to hCA XII is mainly
influenced by the deprotonated sulfonamide group acting as zinc
binding moiety and H-bonds with the conserved residue in all a-
CAs, Thr199. The NO2 group showed its significant role by partici-
pating in electrostatic interactions with Lys67 (compound 11e) or
Asp130 (compound 16e) (Fig. 5A and B). In contrast to the binding
to hCA IX, the isatin moiety of these compounds displayed extra H-
bond interactions with the hCA XII active site. For example, the
isatin moiety in 11e was able to H-bond with Ser132 (Fig. 5A). In
compound 16e, the isatin moiety formed two hydrogen bonds with
Asn62 and Gln92 (Fig. 5B). The additional interaction of the isatin
moiety with hCA XII active site may explain the higher inhibition of
these compounds against hCA XII compared to hCA XI.
Both compounds displayed CDOCKER interaction energy
(11e;50.23 Kcal/mol and44.67 Kcal/mol) (16e;49.78 Kcal/mol
and 45.64 Kcal/mol) higher than AAZ (24.63 Kcal/mol
and 24.67 Kcal/mol) upon interaction with hCA IX and hCA XII,
respectively.
3. Conclusion
Stimulated by the reported activity of several N-benzene sul-
fonamide pyrazoles and isatins as CAIs, new series of isatin-
pyrazole-benzenesulfonamide hybrids 5a¡d, 11a¡f and 16a¡f
were designed and synthesized as inhibitors of several CA isoforms.
The structure of the new compounds was confirmed by spectral
methods and intermediates 10 and 14 were confirmed by using X-
ray crystallography. Biological evaluation of the new compounds
was performed against hCA I, II, IX and XII. Most of the testeding sulfonamide as zinc binding group and nitro group interacting with Asp132 with
I) showing sulfonamide as zinc binding group and nitro group interacting with Asp132
the interacting amino acids were displayed as stick. Hydrogen bond was represented by
was represented by pink dots and metallic bond was represented by gray dots. (For
web version of this article.)
Fig. 5. (A) 3D diagram for interaction of compound 11e with hCA XII (PDB id: 1JD0) showing sulfonamide as zinc binding group and nitro group interacting with Lys67 with
electrostatic bond. (B) 3D diagram for interaction of compound 16ewith hCA XII (PDB id: 1JD0) showing sulfonamide as zinc binding group and nitro group interacting with Asp130
with electrostatic bond. In these diagrams, the whole protein was displayed as a tube except the interacting amino acids were displayed as stick. Hydrogen bond was represented by
green dots, electrostatic bond was represented by orange dots, Pi-hydrophobic interaction was represented by pink dots and metallic bond was represented by gray dots. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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being more effective than the reference drug acetazolamide (AAZ).
On the other hand, they inhibited hCA XII to a lesser extent except
for compounds 11e, 11f 16e and 16f (Ki¼ 3.7, 6.5, 5.4 and 7.2 nM,
respectively). Sulfonamides 11e and 16e with a 5-NO2 substituent
on the isatin ring were found to preferentially inhibit hCA IX and
hCA XII. Docking studies were performed to investigate the role of
the NO2 group and revealed that it can form electrostatic interac-
tion with Asp132 in hCA IX, and with Lys67/Asp130 during inhi-
bition of hCA XII. These results indicate that, the new hybrids
provide an efficient pharmacophore to design CAIs, yet further in-
vestigations are required to improve their selectivity toward the
tumor-associated isoforms hCA IX and XII.
4. Experimental
4.1. Chemistry
Unless otherwise noted, all materials were obtained from
commercial suppliers and used without further purification.
Melting points were determined on Stuart SMP3 version 5 digital
melting point apparatus and were uncorrected. Elemental micro-
analyses were performed at the Regional Center for Mycology and
Biotechnology, Al-Azhar University. The NMR spectra were recor-
ded for some compounds on a Varian Mercury VX-300 NMR
spectrometer. 1H spectrawere run at 300MHz and 13C spectrawere
run at 75 MHz. For other compounds, the NMR spectra were
recorded on Bruker Avance III 400 MHz high performance digital
FT-NMR spectrophotometer (1H: 400, 13C: 100 MHz). Chemical
shifts are quoted in d and were related to that of the solvents. Mass
spectra were recorded using Hewlett Packard Varian (Varian, Polo,
USA), Shimadzu Gas Chromatograph Mass spectrometer-QP 1000
EX (Shimadzu, Kyoto, Japan) and Finnegan MAT, SSQ 7000 mass
spectrophotometer at 70 eV. IR spectrawere recorded on Bruker FT-
IR spectrophotometer as potassium bromide discs. Compounds 2
[26], 7 [27], 8 [28], 9 [19], 13 [29], 15 [30] were prepared and
confirmed as reported.
4.1.1. Synthesis of ethyl 5-phenyl-1-(4-sulfamoylphenyl)-1H-
pyrazole-3-carboxylate (3)
The diketoester, ethyl 2,4-dioxo-4-phenylbutanoate (2)
(4 mmol, 0.88 g) was dissolved in acetic acid (15 mL) and then asolution of 4-aminosulfonylphenylhydrazine (4 mmol, 0.75 g) in
ethanol (20 mL) was added. The reaction mixture was refluxed for
1 h. The formed precipitate was filtered, dried and recrystallized
from ethanol to yield compound 3. All spectral data coincide with
those reported [19].
4.1.2. Synthesis of 4-(3-(hydrazinecarbonyl)-5-phenyl-1H-pyrazol-
1-yl)benzenesulfonamide (4)
The ester 3 (10 mmol, 3.71 g) was refluxed in hydrazine hydrate
(10 mL) and the reaction was followed by TLC. After complete re-
action (3 h), the mixture was poured onto ice and stirred for 1 h
with addition of few drops of acetic acid. The formed precipitate
was filtered off, washed with diethyl ether, dried and recrystallized
from ethanol. Beige crystals, 61% yield; mp 265 C. IR (KBr) nmax/
cm1 3334-3196 (NH2, NH), 1674 (C]O), 1593 (C]N), 1319, 1153
(SO2). 1H NMR (DMSO-d6, 400 MHz) d 4.61 (s, 2H, NH2 hydrazide,
D2O exchangeable), 7.06 (s, 1H, H-4 of pyrazole), 7.29e7.31 (m, 2H,
AreH), 7.38e7.46 (m, 3H, AreH), 7.51 (s, 2H, SO2NH2, D2O
exchangeable), 7.53 (d, 2H, J¼ 8.7 Hz, AreH), 7.88 (d, 2H, J¼ 8.7 Hz,
AreH), 9.69 (s, 1H, NH hydrazide, D2O exchangeable). 13C NMR
(DMSO-d6, 100 MHz) d 108.69,125.99, 127.16, 129.18, 129.32, 129.49,
129.56, 142.07, 143.81, 144.64, 147.32, 161.07. MS m/z [%] 357 [Mþ,
9.84], 326 [100]. Anal. Calcd for C16H15N5O3S (357.39): C, 53.77; H,
4.23; N, 19.60; S, 8.97. Found: C, 53.93; H, 4.29; N, 19.78; S, 9.04.
4.1.3. General procedure for synthesis of compounds (5aed)
To a solution of hydrazide 4 (10 mmol, 0.36 g) in ethanol
(20 mL), the appropriate isatin (10 mmol) was added followed by a
catalytic amount of acetic acid (0.5 mL) then the mixture was
refluxed for 1 h. The formed precipitate was filtered off, washed
with hot ethanol and recrystallized from DMF/ EtOH to give the
targeted compounds 5aed.
4.1.3.1. 4-(3-(2-(2-Oxoindolin-3-ylidene)hydrazine-1-carbonyl)-5-
phenyl-1H-pyrazol-1-yl)benzenesulfonamide (5a). Yellow powder,
89% yield; mp > 300 C. IR (KBr) nmax/cm1 3361-3184 (NH2, NH),
1732, 1701 (C]O), 1516 (C]N), 1325, 1155 (SO2). 1H NMR (DMSO-
d6, 400 MHz) d 6.95 (d, 1H, J¼ 7.8 Hz, H-7 isatin), 7.10 (t, 1H,
J¼ 7.8 Hz, H-5 isatin), 7.28 (s, 1H, H-4 of pyrazole), 7.34e7.38 (m,
2H, AreH), 7.40e7.45 (m, 4H, AreH), 7.53 (s, 2H, SO2NH2, D2O
exchangeable), 7.57 (d, 2H, J¼ 8.7 Hz, AreH), 7.65 (d, 1H, J¼ 7.8 Hz,
H-4 isatin), 7.93 (d, 2H, J¼ 8.7 Hz, AreH), 10.88, 11.22 (2s, 1H, NH
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exchangeable). 13C NMR (DMSO-d6, 100 MHz) d 109.61, 111.54,
116.10, 120.37, 121.44, 122.52, 123.10, 126.09, 126.44, 127.35, 129.03,
129.32,129.72,132.22,133.42,138.45,141.84,143.05,144.40,145.95,
146.09, 158.02, 163.05. MS m/z [%] 486 [Mþ, 8.62], 326 [100]. Anal.
Calcd for C24H18N6O4S (486.51): C, 59.25; H, 3.73; N, 17.27; S, 6.59.
Found: C, 59.37; H, 3.76; N, 17.41; S, 6.67.
4.1.3.2. 4-(3-(2-(5-Chloro-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (5b).
Yellow powder, 56% yield; mp > 300 C. IR (KBr) nmax/cm1 3396-
3221 (NH2, NH), 1720, 1697 (C]O),1517 (C]N),1340, 1157 (SO2). 1H
NMR (DMSO-d6, 400 MHz) d 6.97 (dd, 1H, J¼ 8.3, 3.6 Hz, H-7 of
isatin), 7.31 (s, 1H, H-4 of pyrazole), 7.34e7.49 (m, 6H, AreH), 7.54
(s, 2H, SO2NH2, D2O exchangeable), 7.58 (d, 1H, J¼ 8.9 Hz, H-4
isatin), 7.64 (d, 1H, J¼ 8.6 Hz, AreH), 7.90 (d, 2H, J¼ 8.6 Hz, AreH),
11.00, 11.34 (2s, 1H, NH isatin, D2O exchangeable), 11.69, 14.13 (2s,
1H, NH hydrazone, D2O exchangeable). 13C NMR (DMSO-d6,
100 MHz) d 109.98, 112.84, 117.26, 120.97, 122.12, 125.82, 126.16,
126.31, 126.46,127.20, 127.35, 129.14, 129.34, 129.42, 129.48, 131.26,
132.72, 137.61, 141.72, 143.12, 144.25, 145.63,162.89, 164.77. MS m/z
[%] 522 [Mþþ2, 6.34], 520 [Mþ, 18.60], 222 [100]. Anal. Calcd for
C24H17ClN6O4S (520.95): C, 55.33; H, 3.29; N, 16.13; S, 6.15. Found:
C, 55.51; H, 3.27; N, 16.29; S, 6.22.
4.1.3.3. 4-(3-(2-(5-Bromo-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (5c).
Yellow powder, 87% yield; mp > 300 C. IR (KBr) nmax/cm1 3367-
3219 (NH2, NH), 1725, 1699 (C]O),1516 (C]N),1325,1157 (SO2). 1H
NMR (DMSO-d6, 300 MHz) d 6.94 (dd, 1H, J¼ 8.4, 4.4 Hz, H-7 of
isatin), 7.29 (s, 1H, H-4 of pyrazole), 7.35e7.49 (m, 6H, AreH), 7.48
(s, 2H, SO2NH2, D2O exchangeable), 7.54e7.89 (m, 5H, AreH), 10.94,
11.30 (2s, 1H, NH isatin, D2O exchangeable), 11.61, 14.08 (2s, 1H, NH
hydrazone, D2O exchangeable). MS m/z [%] 566 [Mþþ2, 5.41], 564
[Mþ, 6.16], 326 [100]. Anal. Calcd for C24H17BrN6O4S (565.40): C,
50.98; H, 3.03; N, 14.86; S, 5.67. Found: C, 51.16; H, 3.04; N, 14.95; S,
5.72.
4.1.3.4. 4-(3-(2-(5-Methyl-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (5d).
Yellow powder, 77% yield; mp > 300 C. IR (KBr) nmax/cm1 3344-
3215 (NH2, NH), 1714, 1685 (C]O), 1517 (C]N), 1340, 1166 (SO2). 1H
NMR (DMSO-d6, 300MHz) d 2.30 (s, 3H, CH3), 6.83 (d,1H, J¼ 7.9 Hz,
H-7 of isatin), 7.17 (d, 1H, J¼ 7.9 Hz, H-6 of isatin), 7.26 (s, 1H, H-4 of
pyrazole), 7.27e7.35 (m, 5H, AreH), 7.49 (s, 2H, SO2NH2, D2O
exchangeable), 7.57 (d, 2H, J¼ 8.1 Hz, AreH), 7.65 (d, 1H, J¼ 7.8 Hz,
H-4 isatin), 7.91 (d, 2H, J¼ 8.7 Hz, AreH), 10.81, 11.22 (2s, 1H, NH
isatin, D2O exchangeable), 11.54, 14.13 (2s, 1H, NH hydrazone, D2O
exchangeable). 13C NMR (DMSO-d6, 75 MHz) d 20.48 (CH3), 109.07,
110.87, 119.88, 121.29, 125.37, 125.90, 126.69, 128.54, 129.21, 131.68,
132.13, 138.08, 140.28, 141.34, 143.91, 145.43, 157.50, 162.61. MS m/z
[%] 500 [Mþ, 5.60], 222 [100]. Anal. Calcd for C25H20N6O4S (500.53):
C, 59.99; H, 4.03; N, 16.79; S, 6.41. Found: C, 60.23; H, 4.11; N, 16.93;
S, 6.46.
4.1.4. Synthesis of 4-(4-(hydrazinecarbonyl)-5-phenyl-1H-pyrazol-
1-yl)benzenesulfonamide (10)
Ethyl 5-phenyl-1-(4-sulfamoylphenyl)-1H-pyrazole-4-carboxy
late (9) (10 mmol, 3.71 g) was refluxed with 15 mL of hydrazine
hydrate for 3 h. After checking the end of the reaction using TLC, the
mixture was poured on ice, stirred for 1 h with addition of few
drops of acetic acid. The formed precipitate was filtered off, washed
with diethyl ether, dried and recrystallized from ethanol. Violet
crystals, 77% yield; mp 263e265 C. IR (KBr) nmax/cm1 3398-3219
(2NH2, NH), 1647 (C]O), 1560 (C]N), 1328, 1157 (SO2). 1H NMR(DMSO-d6, 400 MHz) d 4.42 (s, 2H, NH2 hydrazone, D2O
exchangeable), 7.31e7.33 (m, 2H, AreH), 7.35e7.40 (m, 5H, AreH),
7.46 (s, 2H, SO2NH2, D2O exchangeable), 7.79 (d, 2H, J¼ 8.7 Hz,
AreH), 8.21 (s, 1H, H-3 of pyrazole), 9.40 (s, 1H, NH hydrazone, D2O
exchangeable). 13C NMR (DMSO-d6, 100 MHz) d 117.13, 125.82,
126.59,128.54,129.23,129.45,130.98,140.35,141.96,143.49,143.70,
162.23. MS m/z [%] 357 [Mþ, 10.98], 326 [100]. Anal. Calcd for
C16H15N5O3S (357.39): C, 53.77; H, 4.23; N, 19.60; S, 8.97. Found: C,
53.91; H, 4.30; N, 19.76; S, 9.06.
4.1.5. General procedure for synthesis of compounds (11aef)
To a solution of 4-(4-(hydrazinecarbonyl)-5-phenyl-1H-pyrazol-
1-yl)benzenesulfonamide (10) (10 mmol, 0.36 g) in 20 mL ethanol,
10 mmol of 5-(un)substituted isatin or N-benzyl isatin was added
followed by catalytic amount of acetic acid (0.5 mL). The reaction
mixture was refluxed for 1 h. The formed precipitate, in case of
11aee, was filtered, washed with hot ethanol and recrystallized
from DMF/ EtOH to give the targeted compounds 11aee. Con-
cerning compound 11f, the precipitate formed after cooling was
filtered and recrystallized from DMF/ EtOH.
4.1.5.1. 4-(4-(2-(2-Oxoindolin-3-ylidene)hydrazine-1-carbonyl)-5-
phenyl-1H-pyrazol-1-yl)benzenesulfonamide (11a). Yellow powder,
83% yield; mp > 300 C. IR (KBr) nmax/cm1 3278-3136 (NH2, 2NH),
1710-1681 (C]O), 1552 (C]N), 1320, 1153 (SO2). 1H NMR (DMSO-
d6, 300 MHz) d 6.85 (d, 1H, J¼ 7.8 Hz, H-7 isatin), 7.05 (t, 1H, J¼ 7.8,
H-5 isatin), 7.30e7.53 (m, 9H, AreH), 7.50 (s, 2H, SO2NH2, D2O
exchangeable), 7.81 (d, 2H, J¼ 8.4 Hz, AreH), 8.34, 8.47 (2s, 1H, H-3
of pyrazole), 10.74,11.20 (2s, 1H, NH isatin, D2O exchangeable),
10.95, 13.10 (2s, 1H, NH hydrazone, D2O exchangeable). 13C NMR
(DMSO-d6, 75 MHz) d 110.43, 111.06, 115.21, 119.71, 120.77, 121.58,
122.58, 125.77, 125.88, 126.47, 128.01, 129.54, 130.34, 131.52, 132.41,
141.13, 142.11, 143.37, 162.46, 164.60. MSm/z [%] 486 [Mþ, 7.98], 222
[100]. Anal. Calcd for C24H18N6O4S (486.51): C, 59.25; H, 3.73; N,
17.27; S, 6.59. Found: C, 59.37; H, 3.76; N, 17.39; S, 6.64.
4.1.5.2. 4-(4-(2-(5-Chloro-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (11b).
Yellow powder, 61% yield; mp > 300 C. IR (KBr) nmax/cm1 3410-
3186 (NH2, NH),1712-1698 (C]O),1506 (C]N),1350,1165 (SO2). 1H
NMR (DMSO-d6, 400 MHz) d 6.87 (d, 1H, J¼ 8.4 Hz, H-7 of isatin),
6.93 (d, 1H, J¼ 8.4 Hz, H-6 of isatin), 7.33e7.42 (m, 8H, AreH), 7.47
(s, 2H, SO2NH2, D2O exchangeable), 7.77 (d, 2H, J¼ 8.7 Hz, AreH),
8.38, 8.48 (2s, 1H, H-3 of pyrazole), 10.88, 11.33 (2s, 1H, NH isatin,
D2O exchangeable), 11.35, 13.02 (2s, 1H, NH hydrazone, D2O
exchangeable). 13C NMR (DMSO-d6, 100 MHz) d 112.26, 113.09,
116.73, 120.81, 121.92, 126.08, 126.28, 126.41, 127.04, 127.22, 128.80,
128.96, 129.79, 130.71, 130.84, 131.40, 132.26, 141.38, 141.71, 142.81,
143.84, 143.96, 162.76, 164.92. MS m/z [%] 522 [Mþþ2, 3.22], 520
[Mþ, 9.01], 326 [100]. Anal. Calcd for C24H17ClN6O4S (520.95): C,
55.33; H, 3.29; N, 16.13; S, 6.15. Found: C, 55.71; H, 3.34; N, 16.29; S,
6.21.
4.1.5.3. 4-(4-(2-(5-Bromo-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (11c).
Yellow powder, 87% yield; mp > 300 C. IR (KBr) nmax/cm1 3412-
3178 (NH2, NH),1712-1683 (C]O),1506 (C]N),1350,1166 (SO2). 1H
NMR(DMSO-d6, 400MHz) d6.82 (d,1H, J¼ 8.4Hz,H-7of isatin), 6.88
(d,1H, J¼ 8.4 Hz, H-6 of isatin), 7.38e7.45 (m, 8H, AreH), 7.51 (s, 2H,
SO2NH2, D2O exchangeable), 7.82 (d, 2H, J¼ 8.7Hz, AreH), 8.38, 8.47
(2s, 1H, H-3 of pyrazole), 10.89, 11.23 (2s, 1H, NH isatin, D2O
exchangeable), 11.35, 13.01 (2s, 1H, NH hydrazone, D2O exchange-
able). 13C NMR (DMSO-d6, 100 MHz) d 112.74, 113.53, 113.74, 114.79,
117.20, 122.33, 123.55, 126.28, 126.41, 127.04, 128.87, 128.96, 129.76,
130.69, 130.83, 134.18, 135.06, 141.60, 141.75, 142.74, 143.84, 143.95,
H.S. Ibrahim et al. / European Journal of Medicinal Chemistry 103 (2015) 583e593 591162.61, 164.79. MS m/z [%] 566 [Mþþ2, 3.32], 564 [Mþ, 3.56], 326
[100]. Anal. Calcd for C24H17BrN6O4S (565.40): C, 50.98; H, 3.03; N,
14.86; S, 5.67. Found: C, 51.08; H, 3.09; N, 14.97; S, 5.73.
4.1.5.4. 4-(4-(2-(5-Methoxy-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (11d).
Orange powder, 81% yield; mp > 300 C. IR (KBr) nmax/cm13414-
3190 (NH2, NH),1722-1690 (C]O),1512 (C]N),1322,1156 (SO2). 1H
NMR (DMSO-d6, 300 MHz) d 3.77 (s, 3H, OCH3), 6.81 (dd, 1H,
J¼ 11.4, 8.6 Hz, H-7 of isatin), 6.91e7.08 (m, 1H, AreH), 7.30e7.43
(m, 6H, AreH), 7.45 (s, 2H, SO2NH2, D2O exchangeable), 7.80 (d, 2H,
J¼ 8.7 Hz, AreH), 8.34, 8.49 (2s, 1H, H-3 of pyrazole), 10.55, 11.02
(2s, 1H, NH isatin, D2O exchangeable), 11.31, 13.12 (2s, 1H, NH
hydrazone, D2O exchangeable). 13C NMR (DMSO-d6, 75 MHz)
d 55.58, 105.73, 110.91, 111.91, 112.39, 115.65, 118.23, 120.46, 125.74,
126.50, 128.29, 129.23, 130.23, 135.90, 137.35, 141.14, 142.19, 143.31,
154.45, 155.32, 162.60, 164.74. MSm/z [%] 516 [Mþ, 7.62], 326 [100].
Anal. Calcd for C25H20N6O5S (516.53): C, 58.13; H, 3.90; N, 16.27; S,
6.21. Found: C, 58.30; H, 3.96; N, 16.38; S, 6.32.
4.1.5.5. 4-(4-(2-(5-Nitro-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (11e).
Yellow powder, 92% yield; mp > 300 C. IR (KBr) nmax/cm1 3367-
3105 (NH2, NH),1716-1685 (C]O),1523 (C]N),1338,1165 (SO2). 1H
NMR (DMSO-d6, 400 MHz) d 7.08 (dd, 1H, J¼ 19.2, 8.7 Hz, H-7 of
isatin), 7.33e7.46 (m, 5H, AreH), 7.47 (s, 2H, SO2NH2, D2O
exchangeable), 7.82 (d, 2H, J¼ 8.7 Hz, AreH), 8.16e8.42 (m, 4H,
AreH), 8.49, 8.83 (2s, 1H, H-3 of pyrazole), 10.47, 11.86 (2s, 1H, NH
isatin, D2O exchangeable), 11.90, 12.86 (2s, 1H, NH hydrazone, D2O
exchangeable). 13C NMR (DMSO-d6, 100 MHz) d 111.02, 111.84,
115.44, 116.15, 120.94, 122.07, 126.30, 126.43, 127.03, 128.74, 129.02,
129.65, 130.70, 130.82, 141.57, 141.68, 142.35, 143.22, 143.86, 144.00,
147.78, 149.60, 163.20, 165.40. MS m/z [%] 531 [Mþ, 9.67], 324 [30],
125 [100]. Anal. Calcd for C24H17N7O6S (531.50): C, 54.24; H, 3.22; N,
18.45; S, 6.03. Found: C, 54.51; H, 3.28; N, 18.63; S, 6.11.
4.1.5.6. 4-(4-(2-(1-benzyl-2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (11f).
Orange powder, 89% yield; mp¼ 210e212 C. IR (KBr) nmax/cm1
3313-3194 (NH2, NH), 1674-1612 (C]O), 1554 (C]N), 1342, 1168
(SO2). 1H NMR (DMSO-d6, 400 MHz) d 4.93 (s, 2H, benzylic CH2),
7.04 (d, 1H, J¼ 8.7 Hz, H-7 of isatin), 7.11 (t, 1H, J¼ 7.5 Hz, H-5 of
isatin), 7.25e7.40 (m,11H, AreH), 7.47 (d, 2H, J¼ 8.4 Hz, AreH), 7.52
(s, 2H, SO2NH2, D2O exchangeable), 7.56 (d, 1H, J¼ 7.4 Hz, AreH),
7.85 (d, 2H, J¼ 8.4 Hz, AreH), 8.39, 8.57 (2s, 1H, H-3 of pyrazole),
12.00, 13.02 (2s, 1H, NH hydrazone, D2O exchangeable). 13C NMR
(DMSO-d6, 100 MHz) d 42.96, 110.82, 115.85, 119.69, 121.13, 123.74,
126.37, 127.02, 127.96, 128.15, 128.30, 128.99, 129.18, 130.05, 130.89,
131.84, 136.10, 141.62, 142.89, 143.97, 145.40, 161.08, 172.52. MS m/z
[%] 576 [Mþ, 2.03], 144 [100]. Anal. Calcd for C31H24N6O4S (576.63):
C, 64.57; H, 4.20; N, 14.57; S, 5.56. Found: C, 64.74; H, 4.27; N, 14.74;
S, 5.61.
4.1.6. Synthesis of ethyl 5-amino-1-(4-sulfamoylphenyl)-1H-
pyrazole-4-carboxylate (14)
Ethyl 2-cyano-3-ethoxyacrylate (13) (10 mmol, 1.69 g) and 4-
aminobenzenesulfonamide hydrochloride (10 mmol, 2.23 g) were
refluxed in a mixture of acetic acid and water (5:1) for 4 h. The
reaction mixture was poured on ice and stirred for 1 h. The given
precipitate was filtered, washed with water, dried and recrystal-
lized from ethanol. The experimental data were given as reported
[31].
4.1.7. General procedure for synthesis of compounds (16aef)
In 50 mL round flask, 4-(4-(hydrazinecarbonyl)-5-amino-1H-pyrazol-1-yl)benzenesulfonamide 15 (10 mmol, 0.3 g) was dis-
solved in ethanol (20 mL) followed by the addition of the appro-
priate isatin derivative (10 mmol). Reflux was performed after the
addition of a catalytic amount of acetic acid (0.5 mL) for 1 h. The
formed precipitate, in case of 16aee, was filtered washed with hot
ethanol and recrystallized from DMF / EtOH to give the targeted
compounds 16aee. Concerning compound 16f, the precipitate
formed after cooling was filtered and recrystallized from DMF /
EtOH.
4.1.7.1. 4-(5-Amino-4-(2-(2-oxoindolin-3-ylidene)hydrazine-1-
carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide (16a). Yellow pow-
der, 76% yield; mp > 300 C. IR (KBr) nmax/cm1 3385-3182 (NH2,
NH), 1718-1690 (C]O), 1531 (C]N), 1321, 1153 (SO2). 1H NMR
(DMSO-d6, 300 MHz) d 6.52 (s, 2H, NH2, D2O exchangeable),
6.87e7.17 (m, 3H, AreH), 7.37 (t, J¼ 7.8 Hz,1H, AreH), 7.45, 7.50 (2s,
2H, SO2NH2, D2O exchangeable), 7.57 (d, 2H, J¼ 7.5 Hz, AreH),
7.76e8.12 (m , 2H, AreH), 8.53, 9.18 (2s, 1H, H-3 of pyrazole), 10.79,
11.14 (2s, 1H, NH isatin, D2O exchangeable), 11.24, 12.96 (2s, 1H, NH
hydrazone, D2O exchangeable). 13C NMR (DMSO-d6, 75 MHz)
d 95.48, 110.51, 111.04, 115.43, 120.01, 120.55, 121.71, 122.55, 123.52,
125.97, 126.93, 127.03, 131.12, 132.11, 138.77, 140.20, 142.02, 143.57,
151.60, 162.79, 165.02. MS m/z [%] 425 [Mþ, 30.01], 265 [100]. Anal.
Calcd for C18H15N7O4S (425.42): C, 50.82; H, 3.55; N, 23.05; S, 7.54.
Found: C, 51.04; H, 3.53; N, 23.28; S, 7.63.
4.1.7.2. 4-(5-Amino-4-(2-(5-chloro-2-oxoindolin-3-ylidene)hydra-
zine-1-carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide (16b).
Yellow powder, 70% yield; mp > 300 C. IR (KBr) nmax/cm1 3390-
3182 (NH2, NH),1725-1664 (C]O),1521 (C]N),1305,1165 (SO2). 1H
NMR (DMSO-d6, 300 MHz) d 6.52 (s, 2H, NH2, D2O exchangeable),
6.83e7.05 (m, 2H, AreH), 7.34 (t, J¼ 7.8 Hz,1H, AreH), 7.50, 7.63 (2s,
2H, SO2NH2, D2O exchangeable), 7.82 (t, J¼ 6.6 Hz, 2H, AreH),7.99
(d, J¼ 8.4 Hz, 2H, AreH), 8.20, 8.46 (2s, 1H, H-3 of pyrazole), 10.80,
11.34 (2s, 1H, NH isatin, D2O exchangeable), 12.85 (s, 1H, NH
hydrazone, D2O exchangeable). 13C NMR (DMSO-d6, 75 MHz)
d 94.86, 112.43, 120.12, 121.66, 122.64, 123.25, 126.74, 127.01, 130.39,
133.30, 140.18, 140.58, 142.60, 151.68, 162.53. MS m/z [%] 461
[Mþþ2, 3.22], 459 [Mþ, 9.10], 265 [100]. Anal. Calcd for
C18H14ClN7O4S (459.87): C, 47.01; H, 3.07; N, 21.32; S, 6.97. Found:
C, 47.14; H, 3.09; N, 21.57; S, 7.04.
4.1.7.3. 4-(5-Amino-4-(2-(5-Bromo-2-oxoindolin-3-ylidene)hydra-
zine-1-carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide (16c).
Yellow powder, 79% yield; mp > 300 C. IR (KBr) nmax/cm1 3412-
3178 (NH2, NH),1712-1683 (C]O),1506 (C]N),1350,1166 (SO2). 1H
NMR (DMSO-d6, 300 MHz) d 6.52 (s, 2H, NH2, D2O exchangeable),
6.86e7.02 (m, 3H, AreH), 7.49 (s, 2H, SO2NH2, D2O exchangeable),
7.70e7.85 (m, 2H, AreH), 7.99 (d, 2H, J¼ 8.4 Hz, AreH), 8.20, 8.57
(2s, 1H, H-3 of pyrazole), 10.89, 11.33 (2s, 1H, NH isatin, D2O
exchangeable), 12.84 (s, 1H, NH hydrazone, D2O exchangeable). 13C
NMR (DMSO-d6, 75 MHz) d 94.24, 112.87, 114.35, 122.05,
122.84,123.45, 127.01, 133.17, 140.18, 140.95, 142.58, 151.68, 162.38.
MSm/z [%] 505 [Mþþ2, 3.67], 503 [Mþ, 3.69], 222 [100]. Anal. Calcd
for C18H14BrN7O4S (504.32): C, 42.87; H, 2.80; N, 19.44; S, 6.36.
Found: C, 42.99; H, 2.79; N, 19.62; S, 6.39.
4.1.7.4. 4-(5-Amino-4-(2-(5-methoxy-2-oxoindolin-3-ylidene)hydra-
zine-1-carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide (16d).
Orange powder, 85% yield; mp > 300 C. IR (KBr) nmax/cm1 3414-
3190 (NH2, NH),1722-1690 (C]O),1512 (C]N),1322,1156 (SO2). 1H
NMR (DMSO-d6, 400 MHz) d 3.80 (s, 3H, OCH3), 6.82 (d, 1H,
J¼ 8.4 Hz, H-7 isatin), 6.96 (d, 2H, J¼ 10.2 Hz, AreH), 7.07 (s, 2H,
NH2, D2O exchangeable), 7.49 (s, 2H, SO2NH2, D2O exchangeable),
7.83 (d, 2H, J¼ 8.4 Hz, AreH), 8.00 (d, 2H, J¼ 8.4 Hz, AreH), 8.61 (s,
H.S. Ibrahim et al. / European Journal of Medicinal Chemistry 103 (2015) 583e5935921H, H-3 of pyrazole), 10.61, 11.07 (s, 1H, NH isatin, D2O exchange-
able), 11.38, 13.02 (2s, 1H, NH hydrazone, D2O exchangeable). 13C
NMR (DMSO-d6, 100 MHz) d 56.41, 95.92, 111.50, 112.13, 116.20,
118.52, 121.22, 123.18, 123.97, 127.51, 137.77, 140.83, 142.96, 143.31,
152.46,155.11,155.83,165.69,166.47. MSm/z [%] 455 [Mþ, 9.06], 223
[100]. Anal. Calcd for C19H17N7O5S (455.45): C, 50.11; H, 3.76; N,
21.53; S, 7.04. Found: C, 50.27; H, 3.83; N, 21.75; S, 7.13.
4.1.7.5. 4-(5-Amino-4-(2-(5-Nitro-2-oxoindolin-3-ylidene)hydra-
zine-1-carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide (16e).
Yellow powder, 92% yield; mp > 300 C. IR (KBr) nmax/cm1 3421-
3120 (NH2, NH),1732-1666 (C]O),1523 (C]N),1327,1165 (SO2). 1H
NMR (DMSO-d6, 400 MHz) d 6.79e7.14 (m, 2H, AreH), 7.07 (s, 2H,
NH2, D2O exchangeable), 7.51 (s, 2H, SO2NH2, D2O exchangeable),
7.82 (d, 2H, J¼ 8.0 Hz, AreH), 7.99 (d, 2H, J¼ 8.0 Hz, AreH),
8.10e8.39 (m, 1H, AreH), 8.57, 9.16 (2s, 1H, H-3 of pyrazole), 10.98,
11.50 (2s, 1H, NH isatin, D2O exchangeable), 11.95, 12.78 (2s, 1H, NH
hydrazone, D2O exchangeable). 13C NMR (DMSO-d6, 100 MHz)
d 95.72, 110.97, 115.64, 121.89, 123.44, 124.02, 124.07, 127.51, 128.48,
133.07, 140.75, 142.52, 143.03, 143.19, 149.49, 152.61, 165.94. MSm/z
[%] 470 [Mþ, 8.97], 222 [100]. Anal. Calcd for C18H14N8O6S (470.42):
C, 45.96; H, 3.00; N, 23.82; S, 6.82. Found: C, 46.31; H, 2.98; N,
23.94; S, 6.93.
4.1.7.6. 4-(5-Amino-4-(2-(1-benzyl-2-oxoindolin-3-ylidene)hydra-
zine-1-carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide (16f).
Yellow powder, 88% yield; mp¼ 270e272 C. IR (KBr) nmax/cm1
3313-3194 (NH2, NH), 1732-1674 (C]O), 1554 (C]N), 1342, 1168
(SO2).1H NMR (DMSO-d6, 400MHz) d 5.02 (s, 2H, benzylic CH2), 7.03
(s, 2H, NH2, D2O exchangeable), 7.04 (d,1H, J¼ 8.0 Hz, H-7 of isatin),
7.14 (t, 1H, J¼ 7.6 Hz, H-5 of isatin), 7.27e7.42 (m, 6H, AreH), 7.53 (s,
2H, SO2NH2, D2O exchangeable), 7.70 (d, 1H, J¼ 7.4 Hz, AreH), 7.83
(d, 2H, J¼ 8.7 Hz, AreH), 8.00 (d, 2H, J¼ 8.7 Hz, AreH), 8.21 (s, 1H,
H-3 of pyrazole), 12.88 (s, 1H, NH hydrazone, D2O exchangeable).
13C NMR (DMSO-d6, 100 MHz) d 43.00, 95.51, 110.81, 119.98, 120.90,
123.70, 124.01, 127.52, 127.86, 128.09, 129.19, 131.42, 133.89, 136.18,
140.66,142.72,143.13,152.13,161.41. MSm/z [%] 515 [Mþ, 10.12], 326
[100]. Anal. Calcd for C25H21N7O4S (515.55): C, 58.24; H, 4.11; N,
19.02; S, 6.22. Found: C, 58.43; H, 4.16; N, 19.26; S, 6.25.
4.2. Carbonic anhydrase inhibition
4.2.1. CA inhibitory assay
An SX.18 MV-R Applied Photophysics stopped-flow instrument
was used for assaying the CA-catalyzed CO2 hydration activity by
using the method of Khalifah [33]. Inhibitor and enzyme were
preincubated for 6 h. IC50 values were obtained from dose response
curves working at seven different concentrations of test compound
(from 0.1 nM to 50 mM), by fitting the curves using PRISM (www.
graphpad.com) and non-linear least squares methods, values rep-
resenting the mean of at least three different determinations, as
described earlier by us. [32,33] The inhibition constants (KI) were
then derived by using the Cheng-Prusoff equation, as follows:
Ki¼ IC50/(1þ [S]/Km) where [S] represents the CO2 concentration at
which the measurement was carried out, and Km the concentration
of substrate at which the enzyme activity is at half maximal. All
enzymes used were recombinant, produced in E. coli as reported
earlier. [34,35] The concentrations of enzymes used in the assay
were: hCA I, 1031 nM; hCA II, 8.4 nM; hCA IX, 7.8 nM and hCA XII,
10.4 nM.
4.3. X-ray crystallography
4.3.1. General data for compound 10
Single crystals for compounds 10 were obtained by slowevaporation from ethanol. A good crystal with a suitable size was
selected for analysis. Crystallographic data for the structure 10 has
been deposited with the Cambridge Crystallographic Data Center
(CCDC) under the numbers CCDC 1053077. Datawere collected on a
Bruker APEX-II CCD diffractometer equipped with graphite mono-
chromatic Cu Ka radiation (l¼ 1.54178 Å) at 296 (2) K. Cell
refinement and data reduction were done by Bruker SAINT; pro-
gram used to solve structure and refine structure is SHELXS-97 [36].
The final refinement was performed by full-matrix least-squares
techniques with anisotropic thermal data for non-hydrogen atoms
on F2. All the hydrogen atoms were placed in calculated positions
and constrained to ride on their parent atoms. Multiscan absorp-
tion correction was applied by the use of SADABS software.4.3.2. General data for compound 14
Single crystals for compound 14 were obtained by slow evapo-
ration from ethanol. A good crystal with a suitable size was selected
for analysis. Crystallographic data for the structure 14 has been
deposited with the Cambridge Crystallographic Data Center (CCDC)
under the numbers CCDC 1063099. All diagrams and calculations
were performed using maXus [37]. Data were collected on a Kap-
paCCD diffractometer equipped with graphite monochromatic Mo
Ka radiation, l ¼ 0.71073 Å at 298 (2) K. Cell refinement and data
reduction were done by HKL SCALEPACK (Otwinowski & Minor,
1997); program used to solve structure and refine structure is
SHELXS-97 [36]. The final refinement was performed by full-matrix
least-squares techniques with anisotropic thermal data for non-
hydrogen atoms on F2. All the hydrogen atoms were placed in
calculated positions and constrained to ride on their parent atoms.
Multiscan absorption correction was applied by the use of SADABS
software.4.4. Molecular docking studies
The molecular docking of the tested compounds was performed
using Discovery Studio 4 /CDOCKER protocol (Accelrys Software
Inc.). The protein crystallographic structure, hCA IX (PDB id: 3IAI)
and hCA XII (PDB id: 1JD0) was downloaded from the Protein Data
Bank (PDB). The protein was prepared for docking process ac-
cording to the standard protein preparation procedure integrated in
Accelry's discovery studio 4 and prepared by prepare protein pro-
tocol. Docked compounds were drawn and prepared by prepare
ligand protocol to generate 3D structure and refined using
CHARMM force field with full potential. Docking simulations were
run using CDOCKER protocol where maximum bad orientations
was 800 and orientation vdWenergy threshold was 300. Simulated
annealing simulation would be then carried out consisting of a
heating phase 700 K with 2000 steps and a cooling phase back to
5000 steps. The binding energywas calculated as a score to rank the
docking poses. The top 10 docking poses would be finally saved.
Docking poses were ranked according to their eCDOCKER inter-
action energy, and the top pose was chosen for analysis of in-
teractions for each compound.Acknowledgments
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